Patents by Inventor Luke Raymond Zehnder

Luke Raymond Zehnder has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Aryl and heteroaryl fused lactams
    Patent number: 10246433
    Abstract: This invention relates to compounds of general formula (I) in which R1, R2, U, V, L, M, R5, m, X, Y and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.
    Type: Grant
    Filed: May 3, 2017
    Date of Patent: April 2, 2019
    Assignee: Pfizer Inc.
    Inventors: Martin Paul Edwards, Robert Arnold Kumpf, Pei-Pei Kung, Indrawan James McAlpine, Sacha Ninkovic, Eugene Yuanjin Rui, Scott Channing Sutton, John Howard Tatlock, Martin James Wythes, Luke Raymond Zehnder
  • ARYL AND HETEROARYL FUSED LACTAMS
    Publication number: 20170233368
    Abstract: This invention relates to compounds of general formula (I) in which R1, R2, U, V, L, M, R5, m, X, Y and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.
    Type: Application
    Filed: May 3, 2017
    Publication date: August 17, 2017
    Applicant: Pfizer Inc.
    Inventors: Martin Paul EDWARDS, Robert Arnold KUMPF, Pei-Pei KUNG, lndrawan James MCALPINE, Sacha NINKOVIC, Eugene Yuanjin RUI, Scott Channing SUTTON, John Howard TATLOCK, Martin James WYTHES, Luke Raymond ZEHNDER
  • Dihydropyrrolopyrimidine derivatives
    Patent number: 9260439
    Abstract: The present invention relates to compounds of formula (X) or pharmaceutically acceptable salts thereof, wherein R1-R50, a, b, d, e, f, g, h, i, j, k, l, o, p, q, r, s, t, u, y, and z are defined herein. The novel dihydropyrrolopyrimidine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. Additional embodiments relate to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.
    Type: Grant
    Filed: April 2, 2015
    Date of Patent: February 16, 2016
    Assignee: PFIZER INC.
    Inventors: Ping Chen, Hengmiao Cheng, Judith Gail Deal, Gary Michael Gallego, Mehran Jalaie, John Charles Kath, Suvi Tuula Marjukka Orr, Hong Shen, Luke Raymond Zehnder
  • DIHYDROPYRROLOPYRIMIDINE DERIVATIVES
    Publication number: 20150291604
    Abstract: The present invention relates to compounds of formula (X) or pharmaceutically acceptable salts thereof, wherein R1-R50, a, b, d, e, f, g, h, i, j, k, l, o, p, q, r, s, t, u, y, and z are defined herein. The novel dihydropyrrolopyrimidine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. Additional embodiments relate to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.
    Type: Application
    Filed: April 2, 2015
    Publication date: October 15, 2015
    Inventors: Ping CHEN, Hengmiao CHENG, Judith Gail DEAL, Gary Michael GALLEGO, Mehran JALAIE, John Charles KATH, Suvi Tuula Marjukka ORR, Hong SHEN, Luke Raymond ZEHNDER
  • ARYL AND HETEROARYL FUSED LACTAMS
    Publication number: 20150175572
    Abstract: This invention relates to compounds of general formula (I) in which R1, R2, U, V, L, M, R5, m, X, Y and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.
    Type: Application
    Filed: March 9, 2015
    Publication date: June 25, 2015
    Applicant: PFIZER INC.
    Inventors: Martin Paul EDWARDS, Robert Arnold KUMPF, Pei-Pei KUNG, Indrawan James MCALPINE, Sacha NINKOVIC, Eugene Yuanjin RUI, Scott Channing SUTTON, John Howard TATLOCK, Martin James WYTHES, Luke Raymond ZEHNDER
  • Aryl and heteroaryl fused lactams
    Patent number: 9040515
    Abstract: This invention relates to compounds of general formula (I) in which R1, R2, U, V, L, M, R5, m, X, Y and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.
    Type: Grant
    Filed: December 18, 2013
    Date of Patent: May 26, 2015
    Assignee: Pfizer Inc.
    Inventors: Martin Paul Edwards, Robert Arnold Kumpf, Pei-Pei Kung, Indrawan James McAlpine, Sacha Ninkovic, Eugene Yuanjin Rui, Scott Channing Sutton, John Howard Tatlock, Martin James Wythes, Luke Raymond Zehnder
  • ARYL AND HETEROARYL FUSED LACTAMS
    Publication number: 20140179667
    Abstract: This invention relates to compounds of general formula (I) in which R1, R2, U, V, L, M, R5, m, X, Y and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.
    Type: Application
    Filed: December 18, 2013
    Publication date: June 26, 2014
    Applicant: PFIZER INC.
    Inventors: Martin Paul EDWARDS, Robert Arnold KUMPF, Pei-Pei KUNG, Indrawan James MCAPLINE, Sacha NINKOVIC, Eugene Yuanjin RUI, Scott Channing SUTTON, John Howard TATLOCK, Martin James WYTHES, Luke Raymond Zehnder
  • Alpha substituted carboxylic acids
    Publication number: 20050234066
    Abstract: Alpha substituted carboxylic acids of formula (I): wherein R1 and R2 are as defined in the specification and R3 is wherein Y, Ar1, Ar2, Ar3, R4, R5, R6, R7, R8, R9, R9a, R10, R11, R12, R17, ring A, and p are as defined in the specification; pharmaceutical compositions containing effective amounts of said compounds or their salts are useful for treating PPAR, specifically PPAR ?/? related disorders, such as diabetes, dyslipidemia, obesity and inflammatory disorders.
    Type: Application
    Filed: April 15, 2004
    Publication date: October 20, 2005
    Inventors: Simon Bailey, Paul Humphries, Donald Skalitzky, Wei Su, Luke Raymond Zehnder
  • Fused heteroaryl carboxylic acids as PPAR agonists
    Publication number: 20040209929
    Abstract: Fused heteroarylcarboxylic acids of formula (I): 1
    Type: Application
    Filed: February 19, 2004
    Publication date: October 21, 2004
    Applicant: Agouron Pharmaceuticals, Inc.
    Inventors: Donald Skalitzky, Wei-Guo Su, Luke Raymond Zehnder